A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

P. Presgrave*, R. Woods, R. Kefford, D. Bell, D. Raghavan, J. Levi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

4′ Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m2 and 40 mg/m2 respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc < 3 × 109/L occurred in 33% of patients and thrombocytopenia < 100 × 109/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.

Original languageEnglish
Pages (from-to)219-221
Number of pages3
JournalInvestigational New Drugs
Volume6
Issue number3
DOIs
Publication statusPublished - Sep 1988
Externally publishedYes

Keywords

  • 4′demethoxydaunorubicin
  • non small cell lung cancer
  • oral
  • phase II

Fingerprint Dive into the research topics of 'A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer'. Together they form a unique fingerprint.

Cite this